San Diego, CA -- (SBWire) -- 06/02/2017 --An investor in shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX), filed a lawsuit over alleged Securities Laws violations by Akari Therapeutics PLC.
Investors who purchased shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The plaintiff claims that between March 30, 2017, and May 11, 2017 the defendants failed to disclose that the Company's CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin, that the Company lacked adequate checks and protections to prevent such behavior, and that, as a result of the foregoing, Defendants' statements about Akari's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
New York based Akari Therapeutics PLC formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) rose to as high as $21.86 per share on April 21, 2017.
On May 11, 2017, Akari Therapeutics PLC announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb had any involvement with the materially inaccurate research report.
Shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) declined to as low as $6.10 per share on June 1, 2017.
Those who purchased shares of Akari Therapeutics PLC (ADR) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Lawsuit for Investors in NASDAQ:AKTX ADR Shares Against Akari Therapeutics PLC Filed
A lawsuit was filed on behalf of investors in Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares over alleged securities laws violations.